Click on image to view larger version.

Figure 7 Western blotting showing the effects of hydroxyfasudil (HF) on Rho-kinase activity and on eNOS protein expression in the myocardium of LAD and LCX. (a) Rho-kinase activity in coronary artery; (b) expression of eNOS protein in endocardium; (c) expression of eNOS protein in epicardium. Rho-kinase activity was determined by the degree of ezrin-radixin-moesin phosphorylation (p-ERM/t-ERM). Rho-kinase activation in the ischemic LAD was completely inhibited by cotreatment with hydroxyfasudil. Expression of eNOS protein in the ischemic endocardium of LAD area was significantly decreased compared with the non-ischemic endocardium of LCX area, which was again improved by hydroxyfasudil. *p < 0.05, **p < 0.01.